Navigation Links
'Drug-Free' Stent Coating Shows Promise
Date:1/21/2008

Trial finds polymer reduces inflammatory reaction associated with current devices

MONDAY, Jan. 21 (HealthDay News) -- A new kind of coated stent holds promise for overcoming the major problems with these tubes that are inserted to keep arteries open after clot-clearing angioplasty, Italian researchers report.

The new stent is not coated with drugs, like the latest generation in medical use, but with a special polymer designed to prevent thrombosis and restenosis, formation of new clots and buildup of deposits that re-clog the blood vessels, Dr. Corrado Tamburino told the International Symposium of Endovascular Therapy meeting on Monday in Hollywood, Fla.

A trial in which the new stents were inserted in 55 people who underwent angioplasty showed excellent results, said Tamburino, professor of cardiology at the University of Catania, where the procedures were performed.

"We had no thrombosis, no deaths, no myocardial infarctions [heart attacks] at six months," Tamburino said.

In addition, close examination of the arteries showed re-growth of fatty deposits only in the smallest vessels, Tamburino said. "In large vessels, restenosis was nil," he said.

The results were especially remarkable, because one-third of the stent recipients were diabetic and thus more vulnerable to problems, and all participants got only 30 days of the clot-preventing drug Plavix, he said. Current U.S. recommendations are for six months to a year of Plavix after stent implantation.

The polymer used to coat the stent was developed by CeloNova Biosciences, a Georgia-based biotechnology company. It is designed "to reduce inflammation and immune responses to the stent," Tamburino said.

"A polymer coating with almost no inflammatory action is an interesting concept," said Dr. Ramon Quesada, director of interventional cardiology at the Baptist Cardiac and Vascular Institute of Miami, after he heard Tamburino's report. "There is potentially lower chance of thrombosis."

But it's much too early to start drawing definitive conclusions about the new stents, Quesada said. "These are very preliminary data," he said. "We cannot make too much of it because the numbers in the trial are very small. This is an interesting observation, and we have to see the results of more trials."

Future trials would have to match results of angioplasty using existing drug-coated stents with the new polymer-coated stents, Tamburino said. Such trials would take years to produce definitive information, he said.

More information

You can learn more about stents from the American Heart Association.



SOURCES: Corrado Tamburino, M.D., Ph.D., professor of cardiology, University of Catania, Italy; Ramon Quesada, M.D., director of interventional cardiology, Baptist Cardiac and Vascular Institute of Miami; Jan. 21, 2008, meeting, International Symposium of Endovascular Therapy, Hollywood, Fla.


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Drug-free treatments offer hope for older people in pain
2. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
3. Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement
4. Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement
5. Supernanny Jo Frost Joins the Partnership for a Drug-Free America in Supporting Time To Talk(TM)
6. U.S. Secretary of Labor launches Drug-Free Work Week
7. AssistNow Offers Area Employers Complimentary Needs Assessment in Recognition of National Drug-Free Work Week
8. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on the Release of the 2007 Monitoring the Future Study
9. Dr. Drew Joins the Partnership for a Drug-Free America in Supporting TimeToTalk(TM)
10. Statement of Steve Pasierb, President and CEO, Partnership for a Drug-Free America on New SAMHSA Study On Cough Medicine Abuse
11. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
'Drug-Free' Stent Coating Shows Promise
(Date:6/23/2017)... , ... June 23, 2017 , ... MD Now ... This is MD Now’s 28th facility overall and marks the urgent care center's eighth ... one mile North of The Falls shopping mall. The new clinic offers a wide ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ross Insurance Agency ... the Federal Emergency Management Agency’s (FEMA) recent update of flood zones, more people ... the Biggert-Waters Act was enacted to reflect the actual risk in flood zone ...
(Date:6/23/2017)... Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... on 26th June, 2017 from 9 am to 3 pm to present to graduate ... The program is an original curriculum project led by The Health Improvement Service ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... assistance and financial planning services to communities in the greater Chicago metropolitan area, ... to offer assistance to underprivileged youth in Chicago. , Founded in 1897, Hephzibah ...
(Date:6/23/2017)... Morgantown, WV (PRWEB) , ... June 23, 2017 ... ... asset protection services and personal financial planning to families and business owners in ... Stepping Stones organization to help provide services to differently abled residents in the ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: